Quarterly report · Q2
7745.TEDINET S100S809
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥29.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥59.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥27.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥3.2bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥1.8bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥3.4bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥7.6bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.2bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥3.4bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.2bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.5bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.5bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.2bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥1.5bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥71.2bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥69.4bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥66.3bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥36.7bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥36.8bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥34.5bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥32.6bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥32.0bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥16.3bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥15.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥15.6bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.8bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.0bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥3.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥613m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥626m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥452m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥317m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥78.3 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥47.82 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥201.33 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥53.43 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.25 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥78.23 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥201.14 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥53.38 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 48.3% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.8% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.1% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 97
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥12.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥12.8bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.6bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥2.2bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥182m |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥26m |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥4.6bn |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥4.6bn |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥276m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.7bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.4bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥184m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥178m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥4.1bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥246m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥287m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥287m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥34m |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.9bn |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥3.9bn |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥9m |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥284m |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥9.2bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥7.8bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥185m |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥8.4bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥5.8bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.7bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥5.7bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.2bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥15.4bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥12.5bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2.9bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥361m |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥21.1bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥11.2bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥9.9bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.2bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.7bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥5.7bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.2bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥13.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥13.9bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥1.8bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥211m |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥370m |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥29m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥317m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.9bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥245m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4.7bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥252m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥471m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥470m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥52m |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥527m |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥7.0bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.9bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥76m |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥8.2bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥845m |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥17.0bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥13.2bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥817m |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥21.5bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥11.4bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥10.1bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥845m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 610
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任 あずさ監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)矢 嶋 泰 久 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)宮 一 行 男 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 27162000000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 29335000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 59028000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 2232000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 3411000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 7643000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 1465000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 2150000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 5524000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 5313000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 2428000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 6335000000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 32007000000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 34453000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 32574000000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 66315000000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 71153000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 69418000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 53.43 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 78.30 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 201.33 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | 53.38 | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | 78.23 | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | 201.14 | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.481 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.483 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.468 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1YTDDuration | 1401000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYTDDuration | 3180000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 4096000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YTDDuration | -626000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYTDDuration | -613000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -1364000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YTDDuration | -317000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYTDDuration | -1428000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | 452000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1QuarterInstant | 12779000000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant | 15551000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 14315000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration | 59.25 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration | 47.82 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 27845208 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 27845208 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 27845208 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 27845208 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |